Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

NCT07257978 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

RETT Syndrome With Proven MECP2 Mutation
Rett Syndrome

Interventions

DRUG: NTI164
DRUG: Placebo

Sponsor

Fenix Innovation Group

Collaborators

[object Object]